Incyte inks $750M deal for immune and neuro biotech Escient
Incyte said it will pay $750 million to buy San Diego biotech Escient Pharmaceuticals and its pipeline of early-stage drug candidates.
The deal gives the …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
